Organon First Quarter 2025 Earnings Disclaimer statement Cautionary Note Regarding Forward-Looking Statements Except for historical information, this presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management's expectations about Organon's future financial performance and prospects, including expectations regarding regulatory approvals (including t ...

Organon (OGN) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Company Participants Jennifer Halchak - VP, IRKevin Ali - CEOMatthew Walsh - CFOMichael Nedelcovych - Director - Equity ResearchUmer Raffat - Senior Managing DirectorJuan Camilo Ferreira - Executive VP, Head of Research & Development and Chief Medical Officer Conference Call Participants David Amsellem - Sr. Research AnalystEthan Brown - Equity Research AnalystBhavin Patel - Analyst Operator Hello, and welcome to the Organon First Quarter twenty t ...

Organon (OGN) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Speaker0 Hello, and welcome to the Organon First Quarter twenty twenty five Earnings Call and Webcast. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I would now like to turn the conference over to Jennifer Halczek, Vice President, Investor Relations. You may begin. Speaker1 Thank you, operator, and good morning, everyone. Thank you for joining Organon's ...

Exhibit 99.1 (614) 314-8094 Kate Vossen (732) 675-8448 Media Contacts: Karissa Peer Investor Contacts: Jennifer Halchak (201) 275-2711 Renee McKnight (551) 204-6129 Organon Reports Results for the First Quarter Ended March 31, 2025 Company af irms full year 2025 financial guidance, resets dividend payout to strengthen capital structure 1 · Guidance ranges for full year 2025 revenue and Adjusted EBITDA margin are affirmed; company expects to generate over $900 million of free cash flow before one-time costs ...

Wall Street analysts expect Organon (OGN) to post quarterly earnings of $0.92 per share in its upcoming report, which indicates a year-over-year decline of 24.6%. Revenues are expected to be $1.54 billion, down 4.9% from the year-ago quarter. Over the last 30 days, there has been a downward revision of 1.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe. ...

Organon (OGN) closed at $12.20 in the latest trading session, marking a +0.66% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.74%. Elsewhere, the Dow gained 0.05%, while the tech-heavy Nasdaq added 1.26%.The pharmaceutical company's shares have seen a decrease of 16.76% over the last month, not keeping up with the Medical sector's loss of 7.7% and the S&P 500's loss of 4.77%.Investors will be eagerly watching for the performance of Organon in its upcoming earnings ...

Group 1 - Organon closed at $11.30, marking a +1.07% move from the prior day, outperforming the S&P 500 which gained 0.79% [1] - Over the last month, Organon's shares decreased by 26.98%, while the Medical sector lost 8.97% and the S&P 500 lost 3.56% [1] Group 2 - The upcoming earnings release is projected to show earnings per share (EPS) of $0.92, reflecting a 24.59% decrease from the same quarter last year, with revenue estimated at $1.54 billion, indicating a 4.97% decline [2] - For the entire fiscal year, earnings are predicted to be $3.79 per share and revenue at $6.27 billion, showing changes of -7.79% and -2.14% respectively from the previous year [3] Group 3 - Recent shifts in analyst projections for Organon are important as they indicate changing near-term business trends, with upward revisions reflecting analysts' positivity towards the company's operations [4] - Estimate revisions are correlated with near-term share price momentum, and the Zacks Rank system incorporates these changes to provide a practical rating [5] Group 4 - Organon currently holds a Zacks Rank of 3 (Hold), with a Forward P/E ratio of 2.95, which is a discount compared to the industry's average Forward P/E of 14.97 [6] - The PEG ratio for Organon is 1.24, matching the average PEG ratio of the Medical Services industry [7] Group 5 - The Medical Services industry holds a Zacks Industry Rank of 71, placing it in the top 29% of over 250 industries, indicating strong performance potential [7][8]

Organon (OGN) shares soared 8.5% in the last trading session to close at $12.64. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 25.3% loss over the past four weeks.Organon stock surged amid a broader market rebound following the Trump administration’s announcement of a temporary halt on reciprocal tariffs for most countries. The market is also upbeat about Organon’s recently acquired regulatory and commercial rights in the Unite ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Organon (OGN) . This company, which is in the Zacks Medical Services industry, shows potential for another earnings beat.This pharmaceutical company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 3 ...

Company Performance - Organon (OGN) closed at $14.56, down 1.02% from the previous day, underperforming the S&P 500, which fell 0.33% [1] - Over the past month, Organon shares declined by 4.97%, worse than the Medical sector's loss of 3.24% and the S&P 500's loss of 4.03% [1] Upcoming Earnings - Analysts expect Organon to report earnings of $0.92 per share, reflecting a year-over-year decline of 24.59% [2] - Revenue is forecasted to be $1.54 billion, indicating a 4.97% decline compared to the same quarter last year [2] Fiscal Year Estimates - For the fiscal year, earnings are projected at $3.79 per share and revenue at $6.27 billion, representing declines of 7.79% and 2.14% respectively from the prior year [3] - Recent changes in analyst estimates may indicate the company's near-term business trends and overall health [3] Valuation Metrics - Organon has a Forward P/E ratio of 3.88, significantly lower than the industry average of 16.08 [6] - The PEG ratio for Organon is 1.63, compared to the Medical Services industry's average PEG ratio of 1.46 [6] Industry Ranking - The Medical Services industry, part of the Medical sector, holds a Zacks Industry Rank of 71, placing it in the top 29% of over 250 industries [7] - Strong industry rankings correlate with better stock performance, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [7]